Skip to content

US · DMAAR · SHELL COMPANIES

Drugs Made In America Acquisition Corp. Rights (DMAAR) intrinsic value and stock valuation

$0.13as of 2026-11-21 · Mkt cap 361.11M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Drugs Made In America Acquisition Corp. Rights DCF and intrinsic value

InvestorsCraft values DMAAR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DMAAR’s statements →

Drugs Made In America Acquisition Corp. Rights Graham Number

Graham Number: $8.39d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Shell Companies New York, NY 33301 dmaacorp.com

How the business is doing

Fiscal 2024–2025, USD

Revenue
$0.00
20242025
Net income
$5.94M
20242025
Free cash flow
-$-540K
20242025
Total equity
$232.6M
20242025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2024–2025, USD
20252024
Revenue$0.00$0.00
Operating income-$-2.82M-$0.00
Net income$5.94M-$0.00
EPSd$282.7K-$0.00
Operating cash flow-$-540K-$0.00
Capital expenditure$0.00$0.00
Free cash flow-$-540K-$0.00
Total assets$239.9M$0.00
Total debt$0.00$0.00
Net debt-$-10K$0.00
Total equity$232.6M-$0.00
Cash and short-term investments$10K$0.00
Income statement
20252024
Revenue$0.00$0.00
Cost of revenue$0.00$0.00
Gross profit$0.00$0.00
Research and development expenses$0.00$0.00
Selling, general and administrative expenses$2.82M$0.00
Other expenses$0.00$0.00
Operating expenses$2.82M$0.00
Cost and expenses$2.82M$0.00
Interest income$8.76M$0.00
Interest expense$0.00$0.00
Depreciation and amortization$0.00$0.00
Ebitda-$-2.82M-$-280K
Operating income-$-2.82M-$0.00
Total other income/expenses, net$8.76M$0.00
Income before tax$5.94M-$0.00
Income tax expense$0.00$0.00
Net income$5.94M-$0.00
Weighted average shares outstanding$21M$8.57M
Weighted average diluted shares outstanding$21M$8.57M
Balance sheet
20252024
Cash and short-term investments$10K$0.00
Net receivables$0.00$0.00
Inventory$0.00$0.00
Total current assets$10K$0.00
Property, plant and equipment, net$0.00$0.00
Goodwill and intangible assets$0.00$0.00
Long-term investments$0.00$0.00
Total non-current assets$239.9M$0.00
Total assets$239.9M$0.00
Accounts payable$220K$0.00
Short-term debt$0.00$0.00
Deferred revenue$0.00$0.00
Total current liabilities$380K$0.00
Long-term debt$0.00$0.00
Deferred revenue, non-current$0.00$0.00
Total non-current liabilities$6.9M$0.00
Capital lease obligations$0.00$0.00
Total liabilities$7.28M$0.00
Common stock$239.9M$0.00
Retained earnings-$-7.27M-$0.00
Accumulated other comprehensive income (loss)$0.00$0.00
Total equity$232.6M-$0.00
Total investments$0.00$0.00
Total debt$0.00$0.00
Net debt-$-10K$0.00
Cash flow statement
20252024
Net income$3.97M-$0.00
Depreciation and amortization$0.00$0.00
Stock-based compensation$0.00$0.00
Change in working capital$140K$0.00
Accounts receivable$0.00$0.00
Inventory$0.00$0.00
Accounts payable$140K$0.00
Net cash provided by operating activities-$-540K-$-170K
Investments in property, plant and equipment$0.00$0.00
Acquisitions, net$0.00$0.00
Net cash used for investing activities-$-231.15M$0.00
Common stock issued$232.1M-$-330K
Common stock repurchased$0.00$0.00
Dividends paid$0.00$0.00
Net cash used for financing activities$231.7M$170K
Net change in cash$0.00$0.00
Cash at end of period$10K$0.00
Operating cash flow-$-540K-$0.00
Capital expenditure$0.00$0.00
Free cash flow-$-540K-$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Drugs Made In America Acquisition Corp. Rights

        Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate reorganizations.

        CEO
        Roger Bendelac
        Employees
        2
        Beta
        4.01

        Explore

        Frequently asked questions

        What is the intrinsic value of Drugs Made In America Acquisition Corp. Rights (DMAAR)?

        InvestorsCraft does not currently publish an intrinsic value for DMAAR. How the IC value is calculated.

        Is DMAAR undervalued?

        InvestorsCraft does not publish an undervaluation signal for DMAAR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.